BioSpace News Archive

Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Company will release its first quarter 2021 financial results after market close on Thursday, May 6, 2021.

Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021.

DexCom, Inc. reported its financial results as of and for the quarter ended March 31, 2021.

“We have made strong progress in this first quarter, with our new partnership with Merck in long-acting HIV therapies, two newly approved indications in the U.S. for Trodelvy in metastatic triple-negative breast cancer and metastatic urothelial cancer, and the addition of Hepcludex to our portfolio,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.

Gilead Sciences, Inc. announced that the company’s Board of Directors has declared a cash dividend of $0.71 per share of common stock for the second quarter of 2021.

Mirum Pharmaceuticals, Inc., announced that the company will report financial results for the quarter ended March 31, 2021 on Thursday, May 6, 2021.

Significant Regulatory Progress Across Diverse Oncology Pipeline, Including European Commission Approval of TUKYSA, Multiple Applications Under Review Globally for PADCEV, and FDA Acceptance of Tisotumab Vedotin BLA

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, announced that the Company has changed the date of its previously scheduled first quarter 2021 financial results announcement and conference call.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced the pricing of a $500 million senior secured term loan B facility and a $60 million senior secured revolving facility.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2021 and reiterated full-year 2021 guidance for product revenues